Expanded Opioid Panel

HHS Mandatory Guidelines Updates
The Division of Workplace Programs at SAMHSA provided agencies with the option of testing for an expanded opioid panel starting October 1, 2017. Since then, IBC customers have notified the Drug & Alcohol Testing Branch about whether they were adopting the semi-synthetic opioids (oxycodone, oxymorphone, hydrocodone, hydromorphone) panel. If your agency hasn’t made the notification, please email IBCDrugTestingStaff@ibc.doi.gov to let us know about this change to your agency’s lab testing profile.

711 Gallons of Urine in FY17

Contract numbers are in!
In FY17, we continued to support our customers with random testing selection, scheduling, testing, applicant notification, training, and on-site collection services. During the year, we performed 59,892 collections (for all Interior and external customers) and collected 8,246 specimens at the Main Interior Building or while performing on-site testing. The average turnaround time for a result was 1.7 days.

Department of Transportation Updates Panel

Adoption of expanded opioid panel
Starting January 1, 2018, any urine specimen collected under the Department of Transportation regulations (donors who have Commercial Driver's License, fly planes, drive trains, etc.) will automatically be tested for the expanded opioid panel. Agencies do not need to opt-in or out; more info at https://www.transportation.gov/odapc/Part_40_DOT_Policies_Notice_2017

The Interior Business Center is a federal shared services provider that operates under a fee-for-service, full cost recovery business model, offering Acquisition, Financial Management and Human Resources systems and services to federal organizations.